The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys

Blood

Volumn 121, Issue 12, 2013, Pages 2311-2315

  Schwoebel, Frank ^a   Van Eijk, Lucas T ^b   Zboralski, Dirk ^a   Sell, Simone ^a   Buchner, Klaus ^a   Maasch, Christian ^a   Purschke, Werner G ^a   Humphrey, Martin ^c   Zöllner, Stefan ^a   Eulberg, Dirk ^a   Morich, Frank ^d   Pickkers, Peter ^b   Klussmann, Sven ^a  

^a NOXXON PHARMA AG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Drug Development Consultancy and Services   (Germany)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; FERROPORTIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; IRON; NOX H 94; OLIGORIBONUCLEOTIDE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; NOX H94; NOX-H94;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; IC50; IRON BLOOD LEVEL; MACACA FASCICULARIS; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; BLOOD; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ERYTHROCYTE; INFLAMMATION; IRON METABOLISM DISORDER; METABOLISM; MOUSE; PATHOLOGY;

ANEMIA; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTES; HEMOGLOBINS; INFLAMMATION; INTERLEUKIN-6; IRON; IRON METABOLISM DISORDERS; MACACA FASCICULARIS; MACROPHAGES; MALE; MICE; OLIGORIBONUCLEOTIDES;

MLCS; MLOWN;

EID: 84877930663     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-456756     Document Type: Article

References (25)

1. Krause A, Neitz S, Mägert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480(2-3):147-150.
2. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806-7810.
3. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-7819.
4. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-788.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
6. Roy CN, Mak HH, Akpan I, et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007;109(9):4038-4044.
7. Małyszko J, Małyszko JS, Hryszko T, et al. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol. 2005;25(6):586-590.
8. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11): 3262-3267.
9. Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627-3634.
10. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010; 115(17):3616-3624.
11. Hashizume M, Uchiyama Y, Horai N, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2010;30(7):917-923.
12. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110(6):2140-2147.
13. Klussmann S, Nolte A, Bald R, et al. Mirror-image RNA that binds D-adenosine. Nat Biotechnol. 1996;14(9):1112-1115.
14. Eulberg D, Jarosch F, Vonhoff S, et al. Spiegelmers for therapeutic applications – use of chiral principles in evolutionary selection techniques. In: Klussmann S, ed. The Aptamer Handbook: Functional Oligonucleotides and Their Applications. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2006:417-442.
15. Hoffmann S, Hoos J, Klussmann S, et al. RNA aptamers and Spiegelmers: synthesis, purification, and post-synthetic PEG conjugation. Curr Protoc Nucleic Acid Chem. 2011;Chapter 4: Unit 4.46.1-30.
16. Kulkarni O, Pawar RD, Purschke W, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol. 2007;18(8):2350-2358.
17. Sayyed SG, Hägele H, Kulkarni OP, et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia. 2009;52(11):2445-2454.
18. Purschke WG, Eulberg D, Buchner K, et al. An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc Natl Acad Sci USA. 2006;103(13):5173-5178.
19. Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006;107(10):4142-4148.
20. Nieken J, Mulder NH, Buter J, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood. 1995;86(3):900-905.
21. Herodin F, Mestries JC, Janodet D, et al. Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood. 1992;80(3):688-695.
22. Dinant HJ, de Maat CE. Erythropoiesis and mean red-cell lifespan in normal subjects and in patients with the anaemia of active rheumatoid arthritis. Br J Haematol. 1978;39(3):437-444.
23. Dallalio G, Law E, Means RT, Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood. 2006; 107(7):2702-2704.
24. Kemna E, Pickkers P, Nemeth E, et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106(5):1864-1866.
25. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276.